Suppr超能文献

COVID-19 与实体器官移植:疾病严重程度和临床最新进展。

COVID-19 in Solid Organ Transplantation: Disease Severity and Clinical Update.

机构信息

Department of Medicine, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

Enterprise Analytics, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania.

出版信息

Transplant Proc. 2021 May;53(4):1227-1236. doi: 10.1016/j.transproceed.2021.02.014. Epub 2021 Feb 25.

Abstract

BACKGROUND

Solid organ transplant (SOT) recipients are a complex, immunocompromised population in whom greater coronavirus disease 2019 (COVID-19) mortality has been reported compared with the general population.

METHODS

We examined a retrospective cohort of 58 SOT recipients with first-wave COVID-19, comparing patients with severe and nonsevere illness. Additionally, SOT recipients are compared with general patients with first-wave COVID-19.

RESULTS

Organs transplanted included 38 kidneys, 8 livers, 5 hearts, and 3 pancreases. Average SOT recipient age was 57.4 years; 62% were male; 46.6% were African American 36.2% were white. Comorbidities included hypertension (86%), chronic kidney disease (86%), diabetes mellitus (50%), coronary artery disease (26%), and chronic obstructive pulmonary disease (14%). Twenty patients had severe COVID-19 (34.5%) and 38 had nonsevere disease (65.5%). Severe disease was more common in older SOT recipients with comorbidities and was associated with cough, dyspnea, pneumonia, C-reactive protein >10 mg/L, and platelet count <150/μL. Sex, race, body mass index, time from transplant, baseline immunosuppression, and diagnosis month did not differ among those with severe and nonsevere COVID-19. Seventy percent of SOT recipients were hospitalized vs 27.2% of general patients with COVID-19 and inpatient SOT recipients had a higher mechanical ventilation rate. Though a trend toward longer length of stay, higher intensive care unit admission, and greater inpatient mortality was observed (19.5% vs 14.8%), these differences were not significant.

CONCLUSIONS

The severe acute respiratory syndrome coronavirus 2 has greatly impacted SOT recipients. One-third of our SOT recipients seen during the first wave had severe illness with associated standard risk factors for poor outcome. Compared with general first-wave patients, more SOT recipients were hospitalized, although inpatient COVID-19 mortality did not significantly differ.

摘要

背景

实体器官移植(SOT)受者是一个复杂的免疫功能低下人群,与普通人群相比,COVID-19 死亡率更高。

方法

我们研究了 58 例首例 COVID-19 的 SOT 受者的回顾性队列,比较了重症和非重症患者。此外,还将 SOT 受者与首例 COVID-19 的普通患者进行了比较。

结果

移植的器官包括 38 个肾脏、8 个肝脏、5 个心脏和 3 个胰腺。SOT 受者平均年龄为 57.4 岁;62%为男性;46.6%为非裔美国人,36.2%为白人。合并症包括高血压(86%)、慢性肾脏病(86%)、糖尿病(50%)、冠状动脉疾病(26%)和慢性阻塞性肺疾病(14%)。20 例患者患有严重 COVID-19(34.5%),38 例患者患有非严重疾病(65.5%)。患有严重疾病的 SOT 受者年龄较大,合并症较多,伴有咳嗽、呼吸困难、肺炎、C 反应蛋白>10mg/L 和血小板计数<150/μL。严重和非严重 COVID-19 患者之间的性别、种族、体重指数、移植后时间、基础免疫抑制和诊断月份无差异。70%的 SOT 受者住院,而 COVID-19 普通患者住院率为 27.2%,住院 SOT 受者的机械通气率更高。尽管观察到住院时间延长、重症监护病房入住率升高和住院死亡率增加的趋势(19.5%比 14.8%),但这些差异无统计学意义。

结论

严重急性呼吸综合征冠状病毒 2 对 SOT 受者影响很大。我们观察到首例 COVID-19 期间,三分之一的 SOT 受者病情严重,预后不良的相关标准危险因素存在。与普通首例患者相比,更多的 SOT 受者住院,但住院 COVID-19 死亡率无显著差异。

相似文献

1
10
Sepsis outcomes in solid organ transplant recipients.实体器官移植受者的脓毒症结局
Transpl Infect Dis. 2020 Feb;22(1):e13214. doi: 10.1111/tid.13214. Epub 2019 Dec 2.

引用本文的文献

本文引用的文献

2
Antivirals for COVID-19: A critical review.用于治疗新型冠状病毒肺炎的抗病毒药物:一项批判性综述。
Clin Epidemiol Glob Health. 2021 Jan-Mar;9:90-98. doi: 10.1016/j.cegh.2020.07.006. Epub 2020 Jul 28.
5
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.巴瑞替尼联合瑞德西韦治疗住院的新冠成年患者
N Engl J Med. 2021 Mar 4;384(9):795-807. doi: 10.1056/NEJMoa2031994. Epub 2020 Dec 11.
10
Update From the Advisory Committee on Immunization Practices.免疫实践咨询委员会的最新消息。
J Pediatric Infect Dis Soc. 2020 Dec 31;9(6):645-649. doi: 10.1093/jpids/piaa144.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验